The patent protects ActaSim’s design that allows surgeons to use it with ease.
“Receiving the patent is important. It’s also validating seeing the AcatStim-S design so well received by patients and surgeons,” Chris McAuliffe, Theragen’s CEO, said in an Oct. 4 press release. “Our first patent focused on device connectivity, while this patent protects our device design. ActaStim-S offers significant practical advantages versus large, obtrusive devices that can constrain ambulation and mobility.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
